ArticleBlood advances2022

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.

Sangeetha Venugopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.